Zobair M Younossi1, Maria Stepanova2, Mark Sulkowski3, Susanna Naggie4, Massimo Puoti5, Chloe Orkin6, Sharon L Hunt1. 1. Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia. 2. Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia Center for Outcomes Research in Liver Diseases, Washington, D.C. 3. John Hopkins University, Baltimore, Maryland. 4. Duke Medical Center, Durham, North Carolina. 5. Division of Infectious Diseases, AO Ospedale Niguarda Ca' Granda, Milan, Italy. 6. Barts Health NHS Trust, London, United Kingdom.
Abstract
BACKGROUND: Sofosbuvir-containing regimens have been approved for treatment of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected patients. We assessed the effect of treatment with sofosbuvir and ribavirin on patient-reported outcomes (PROs) in individuals with HIV/HCV coinfection. METHODS: HIV/HCV-coinfected patients were treated for 12 or 24 weeks with sofosbuvir and ribavirin. Matched HCV-monoinfected controls were also evaluated. All subjects completed standard PRO questionnaires before, during, and after treatment. RESULTS: Included were 497 participants from the PHOTON-1 and PHOTON-2 clinical trials. At baseline, more impairment in PRO scores was noted in HIV/HCV-coinfected patients, compared with HCV-monoinfected patients. During treatment, moderate decrements in PRO scores (change, up to -6.8% on a 0%-100% scale; P = .0053) were experienced regardless of treatment duration and were similar to those for HCV-monoinfected patients (all P > .05). In 413 HIV/HCV-coinfected patients with a virologic response sustained for 12 weeks after treatment cessation, most PRO scores improved (change, up to +7.6%; P < .0001), similar to findings for HCV-monoinfected patients. In multivariate analysis, in addition to clinico-demographic predictors, coinfection with HIV was associated with PRO impairment at baseline (beta, up to -7.6%; P < .002) but not with treatment-emergent changes in PRO scores (all P > .05). CONCLUSIONS: Patients with HIV/HCV coinfection tolerate interferon-free sofosbuvir-based anti-HCV regimens well and, despite the presence of some baseline impairment, have treatment-emergent changes in PRO scores that are similar to those of patients with HCV monoinfection. CLINICAL TRIALS REGISTRATION: NCT01667731 (PHOTON-1), NCT01783678 (PHOTON-2), NCT01604850 (FUSION), and NCT01682720 (VALENCE).
BACKGROUND:Sofosbuvir-containing regimens have been approved for treatment of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infectedpatients. We assessed the effect of treatment with sofosbuvir and ribavirin on patient-reported outcomes (PROs) in individuals with HIV/HCV coinfection. METHODS:HIV/HCV-coinfectedpatients were treated for 12 or 24 weeks with sofosbuvir and ribavirin. Matched HCV-monoinfected controls were also evaluated. All subjects completed standard PRO questionnaires before, during, and after treatment. RESULTS: Included were 497 participants from the PHOTON-1 and PHOTON-2 clinical trials. At baseline, more impairment in PRO scores was noted in HIV/HCV-coinfectedpatients, compared with HCV-monoinfected patients. During treatment, moderate decrements in PRO scores (change, up to -6.8% on a 0%-100% scale; P = .0053) were experienced regardless of treatment duration and were similar to those for HCV-monoinfected patients (all P > .05). In 413 HIV/HCV-coinfectedpatients with a virologic response sustained for 12 weeks after treatment cessation, most PRO scores improved (change, up to +7.6%; P < .0001), similar to findings for HCV-monoinfected patients. In multivariate analysis, in addition to clinico-demographic predictors, coinfection with HIV was associated with PRO impairment at baseline (beta, up to -7.6%; P < .002) but not with treatment-emergent changes in PRO scores (all P > .05). CONCLUSIONS:Patients with HIV/HCV coinfection tolerate interferon-free sofosbuvir-based anti-HCV regimens well and, despite the presence of some baseline impairment, have treatment-emergent changes in PRO scores that are similar to those of patients with HCV monoinfection. CLINICAL TRIALS REGISTRATION: NCT01667731 (PHOTON-1), NCT01783678 (PHOTON-2), NCT01604850 (FUSION), and NCT01682720 (VALENCE).
Authors: Zobair M Younossi; Maria Stepanova; Linda Henry; Edward Gane; Ira M Jacobson; Eric Lawitz; David Nelson; Fatema Nader; Sharon Hunt Journal: J Hepatol Date: 2013-12-11 Impact factor: 25.083
Authors: Colette J Smith; Lene Ryom; Rainer Weber; Philippe Morlat; Christian Pradier; Peter Reiss; Justyna D Kowalska; Stephane de Wit; Matthew Law; Wafaa el Sadr; Ole Kirk; Nina Friis-Moller; Antonella d'Arminio Monforte; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren Journal: Lancet Date: 2014-07-19 Impact factor: 79.321
Authors: Mark S Sulkowski; Susanna Naggie; Jacob Lalezari; Walford Jeffrey Fessel; Karam Mounzer; Margaret Shuhart; Anne F Luetkemeyer; David Asmuth; Anuj Gaggar; Liyun Ni; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Maribel Rodriguez-Torres; Douglas Dieterich Journal: JAMA Date: 2014 Jul 23-30 Impact factor: 56.272
Authors: Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391
Authors: Stuart C Gordon; Andrew J Muir; Joseph K Lim; Brian Pearlman; Curtis K Argo; Ananthakrishnan Ramani; Benedict Maliakkal; Imtiaz Alam; Thomas G Stewart; Monika Vainorius; Joy Peter; David R Nelson; Michael W Fried; K Rajender Reddy Journal: J Hepatol Date: 2014-09-10 Impact factor: 25.083
Authors: Zobair M Younossi; Maria Stepanova; Mark Sulkowski; Graham R Foster; Nancy Reau; Alessandra Mangia; Keyur Patel; Norbert Bräu; Stuart K Roberts; Nezam Afdhal; Fatema Nader; Linda Henry; Sharon Hunt Journal: Clin Infect Dis Date: 2016-07-20 Impact factor: 9.079
Authors: Bernhard Scheiner; Philipp Schwabl; Sebastian Steiner; Theresa Bucsics; David Chromy; Maximilian C Aichelburg; Katharina Grabmeier-Pfistershammer; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger; Mattias Mandorfer Journal: Medicine (Baltimore) Date: 2016-07 Impact factor: 1.889
Authors: Zobair M Younossi; Maria Stepanova; Rafael Esteban; Ira Jacobson; Stefan Zeuzem; Mark Sulkowski; Linda Henry; Fatema Nader; Rebecca Cable; Mariam Afendy; Sharon Hunt Journal: Medicine (Baltimore) Date: 2017-02 Impact factor: 1.889
Authors: Zobair M Younossi; Louis L LaLuna; John J Santoro; Flavia Mendes; Victor Araya; Natarajan Ravendhran; Lisa Pedicone; Idania Lio; Fatema Nader; Sharon Hunt; Andrei Racila; Maria Stepanova Journal: BMC Gastroenterol Date: 2016-04-04 Impact factor: 3.067
Authors: Giovanni Cenderello; Stefania Artioli; Claudio Viscoli; Ambra Pasa; Mauro Giacomini; Barbara Giannini; Chiara Dentone; Laura Ambra Nicolini; Giovanni Cassola; Antonio Di Biagio Journal: Clinicoecon Outcomes Res Date: 2015-12-31
Authors: Zobair M Younossi; Maria Stepanova; Henry L Y Chan; Mei H Lee; Ming-Lung Yu; Yock Y Dan; Moon S Choi; Linda Henry Journal: Medicine (Baltimore) Date: 2016-03 Impact factor: 1.889